Concentration of ofloxacin in human gingival crevicular fluid after oral administration of Tarivid®

Higashi, Kiyotsugu; Seike, Mayumi; Mitani, Yoko; Morisaki, Katsuhiko; Hayashi, S.; Kitamura, Masahiro; Fujimoto, Naoki; Kimura, Shigenobu; Ebisu, Shigeyuki; Okada, Hiroshi

doi:10.1111/j.1600-0765.1989.tb00890.x

Cited by 21 publications

(6 citation statements)

References 7 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…O maior problema tem o sido o desenvolvimento de ensaios com limite de detecção que permita a quantificação de agentes antibacterianos presentes em volumes pequenos (0,5 µL) de fluido crevicular gengival (Medlicott et al, 1994). Assim, vários autores têm desenvolvido ensaios microbiológicos (Gordon et al, 1980;Goodson et al, 1983;Freeman et al, 1992;Higashi et al, 1991;Notten et al, 1982) e de cromatografia líquida de alta eficiência (Holborow et al, 1988;Higashi et al, 1989;Britt, Pohlod, 1986;Stoltze, 1992) para quantificação de alguns agentes terapêuticos liberados no fluido crevicular gengival a partir de SLIBP.…”

Section: Avaliação Da Efetividade Do Tratamento Da Doença Periodontalunclassified

Sistemas de liberação de fármaco intrabolsa periodontal

Bruschi

Panzeri

Freitas

et al. 2006

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

A doença periodontal é morbidade com alta prevalência na população mundial. É causada pelo acúmulo de componentes microbianos do biofilme dental no interior das áreas subgengivais do periodonto, desencadeando processo inflamatório que afeta as estruturas de suporte dental, resultando em formação de bolsa periodontal e perda dos dentes, se não tratada. O tratamento convencional consiste de raspagem e alisamento radicular, associado ou não ao uso de antimicrobianos de ação sistêmica, o que implica altas doses, porém com eficácia reduzida, efeitos adversos e dificuldades de adesão ao tratamento por parte do paciente. Nas últimas décadas, o tratamento tem sido otimizado pelo uso de sistemas de liberação de fármaco intrabolsa periodontal, com a vantagem de liberar o fármaco no local de ação, possibilitando prolongar e/ou controlar sua concentração. A presente revisão aborda os principais sistemas de liberação de fármaco intrabolsa periodontal, o potencial de utilização, assim como os protocolos disponíveis para a avaliação da efetividade dos mesmos na terapia periodontal.

show abstract

Section: Avaliação Da Efetividade Do Tratamento Da Doença Periodontalunclassified

Sistemas de liberação de fármaco intrabolsa periodontal

Bruschi

Panzeri

Freitas

et al. 2006

Rev. Bras. Cienc. Farm.

View full text Add to dashboard Cite

show abstract

“…Azithromycin exhibits excellent ability to penetrate into both normal and pathological periodontal tissues (12, 64). Fluoroquinolones also penetrate readily into periodontal tissue and gingival crevicular fluid and may reach even higher concentrations than in serum (10, 20, 43, 84). In contrast to earlier studies, Sakkelari et al (100) found that the average concentration of systemically administered tetracyclines in gingival crevicular fluid was less than in plasma and varied widely among individuals (between 0 and 8 μg/ml), with approximately 50% of samples not achieving levels of 1 μg/ml, possibly explaining much of the variability in clinical response to systemic tetracyclines observed in practice.…”

Section: General Considerations In Antibiotic Therapymentioning

confidence: 99%

Systemic antibiotics in the treatment of periodontal disease

Slots¹,

Ting²

2002

Periodontology 2000

205

182

View full text Add to dashboard Cite

“…Data about the level of moxifloxacin within gingival crevicular fluid are not available, but similar levels as measured for ofloxacin, as an example of another fluoroquinolone, might be assumed. Evaluation of a controlled-release insert consisting of 11 % ofloxacin showed concentrations of 1700 µg ml −1 at 3 h after insertion, which decreased to 10 µg ml −1 after 1 day (Higashi et al , 1989). A general problem associated with antibacterials use is the development of resistance.…”

Section: Discussionmentioning

confidence: 99%

Antibacterial activity of moxifloxacin on bacteria associated with periodontitis within a biofilm

Tsaousoglou

Nietzsche

Cachovan

et al. 2014

Journal of Medical Microbiology

View full text Add to dashboard Cite

The activity of moxifloxacin was compared with ofloxacin and doxycycline against bacteria associated with periodontitis within a biofilm (single strain and mixed population) in vitro. MICs and minimal bactericidal concentrations (MBCs) of moxifloxacin, ofloxacin and doxycyline were determined against single strains and mixed populations in a planktonic state. Single-species biofilms of two Porphyromonas gingivalis and two Aggregatibacter actinomycetemcomitans strains and a multispecies biofilm consisting of 12 species were formed for 3 days. The minimal biofilm eradication concentrations (MBECs) were determined after exposing the biofilms to the antibacterials (0.002-512 mg ml "1 ) for 18 h, addition of nutrient broth for 3 days and subsequent subcultivation. Photographs were taken using confocal laser-scanning microscopy and scanning electron microscopy. The MICs and MBCs did not differ between ofloxacin and moxifloxacin against A. actinomycetemcomitans, whilst moxifloxacin was more active than the other tested antibacterials against anaerobes and the mixed population. The single-species biofilms were eradicated by moderate concentrations of the antibacterials, and the lowest MBECs were always found for moxifloxacin (2-8 mg ml "1 ). MBECs against the multispecies biofilms were 128, .512 and .512 mg ml "1 for moxifloxacin, ofloxacin and doxycycline, respectively. In summary, moxifloxacin in a topical formulation may have potential as an adjunct to mechanical removal of the biofilms.

show abstract

Concentration of ofloxacin in human gingival crevicular fluid after oral administration of Tarivid®

Cited by 21 publications

References 7 publications

Sistemas de liberação de fármaco intrabolsa periodontal

Sistemas de liberação de fármaco intrabolsa periodontal

Systemic antibiotics in the treatment of periodontal disease

Antibacterial activity of moxifloxacin on bacteria associated with periodontitis within a biofilm

Contact Info

Product

Resources

About